Investment
Features
FeesSafety
Academy
More
Pluang+

Novo Nordisk raises full-year outlook but pipeline doubts persist amid Eli Lilly competition

Market News
05 Aug 2026
CNBC
View Source
Bearish
Novo Nordisk raises full-year outlook but pipeline doubts persist amid Eli Lilly competition

Novo Nordisk raised its full-year sales and profit outlook, expecting a smaller decline than previously forecasted, driven by strong GLP-1 product sales including the Wegovy pill. However, analysts remain cautious as the better-than-expected quarter was partly due to temporary rebate adjustments, and obesity drug sales were mostly in line with expectations. The company also reported disappointing clinical results for its next-generation weight-loss drug CagriSema, raising concerns about its long-term pipeline. Intense competition from Eli Lilly's newer obesity drugs continues to pressure Novo Nordisk's market position, leaving investors uncertain about sustainable growth prospects.

More News (NVO)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App